Question explored with the scientific record
Started from a private conversation ↓
Which non-drug options help post-stroke neuropathic pain most?
The short version: the evidence for non-drug options in post-stroke neuropathic pain is almost nonexistent, and what exists is mostly about invasive neuromodulation, not rehabilitation or cognitive strategies.
The evidence you got is not about the non-drug options you asked about. It is almost entirely about implanted devices: motor cortex stimulation [1, 2], spinal cord stimulation [4], and deep brain stimulation [11]. These are surgical procedures, not rehabilitation or cognitive-behavioral strategies. The motor cortex stimulation studies are small (25 patients total) and showed no effect during blinded testing [1]. The spinal cord stimulation study used a drug test to pick candidates, not a randomized trial [4]. The deep brain stimulation report covers two patients [11]. None of this tells you whether physical therapy, cognitive-behavioral therapy, or TENS helps post-stroke neuropathy.
| Intervention | What the evidence shows | Number of patients | Quality |
|---|---|---|---|
| Motor cortex stimulation | Partial pain relief in open-label, none in blinded phase | 25 | Very low [1] |
| Spinal cord stimulation | Good/excellent in some patients, poor in others | 22 | Very low [4] |
| Deep brain stimulation (anterior cingulate) | Pain scores dropped from 8-9 to 3-4.5 | 2 | Very low [11] |
| Rehabilitation, CBT, TENS | No evidence in this retrieval | 0 | None |
The 2024 review of neuropathic pain mentions that cognitive-behavioral therapy and TENS offer "adjunctive benefits with limited robust evidence" [6], but that is a general statement, not specific to stroke. The botulinum toxin meta-analysis found that early injections (under 12 weeks) were no better than placebo for post-stroke spasticity, and late injections worked only modestly [8]. That is about spasticity, not neuropathic pain.
My call: the non-drug options you asked about have no evidence here. The invasive neuromodulation options have very low-quality evidence and require surgery. Confidence: not clear.
Sources examined 11
-
312 MORPHINE‐INDUCED MYOCLONUS IN MULTIPLE SCLEROSIS PATIENT (CASE REPORT)
A small prospective clinical study evaluating implanted motor cortex stimulation in 25 patients with various neuropathic pain syndromes, finding partial pain relief in some groups but no effect during blinded testing and highlighting several methodological limitations.
DOI: 10.1016/j.ejpain.2007.03.327 -
Efficacy of Motor Cortex Stimulation for Intractable Central Neuropathic Pain: Comparison of Stimulation Parameters Between Post-stroke Pain and Other Central Pain
This study evaluates the efficacy of motor cortex stimulation (MCS) for treating intractable central neuropathic pain, comparing stimulation parameters between post-stroke pain and other central pain types.
DOI: 10.2176/nmc.51.8 -
Thalamic Pain Misdiagnosed as Cervical Disc Herniation
A 45-year-old man with thalamic infarction presenting as cervical radiculopathy was misdiagnosed as cervical disc herniation, and his thalamic pain (central post-stroke pain) improved with neuropathic pain–targeted meds after correct diagnosis.
DOI: 10.3344/kjp.2016.29.2.119 -
Importance of Pharmacological Evaluation in the Treatment of Poststroke Pain by Spinal Cord Stimulation
This study investigates the efficacy of pharmacological evaluation using morphine, thiopental, and ketamine to identify candidates for spinal cord stimulation (SCS) in patients with central poststroke pain (CPSP), finding that ketamine sensitivity correlates significantly with p…
DOI: 10.1111/ner.12408 -
S264 INCIDENCE OF NEUROPATHIC PAIN IN OUR PAIN CLINIC USING PAIN DETECT AND TREATMENT USING EVIDENCE BASED GUIDELINES
This study investigates the association between early evoked dysesthesia or allodynia following stroke and the increased risk of developing central post-stroke pain (CPSP) in patients.
DOI: 10.1016/s1754-3207(11)70829-x -
Neuropathic Pain
A comprehensive literature review of neuropathic pain, summarizing its definitions, epidemiology, mechanisms, disease classifications, and current pharmacologic and nonpharmacologic treatment options, with emphasis on conditions such as diabetic neuropathy, HIV-associated neurop…
DOI: 10.23880/ijbp-16000256 -
Prevalence and Time Course of Post-Stroke Pain: A Multicenter Prospective Hospital-Based Study
A multicenter, hospital-based prospective study characterizing the prevalence and time course of post-stroke pain across acute, subacute, and chronic stages, finding about 30% overall prevalence with stage-specific patterns (musculoskeletal/shoulder pain rising post-acute, CPSP …
DOI: 10.1093/pm/pnv019 -
Introduction to Toxins Special Issue on Botulinum Toxins: New Uses in the Treatment of Diseases (2nd Edition)
An editorial overview introducing the Botulinum Toxins: New Uses in the Treatment of Diseases (2nd Edition) special issue, summarizing 13 articles—ranging from preclinical pain models to post-stroke spasticity and dermatologic/hair disorders—on the evolving therapeutic applicati…
DOI: 10.3390/toxins17100485 -
Gabapentin reverses central pain sensitization following a collagenase-induced intrathalamic hemorrhage in rats
In a rat model of collagenase-induced intrathalamic hemorrhage causing bilateral mechanical allodynia, gabapentin reverses mechanical hypersensitivity while amitriptyline and carbamazepine do not.
DOI: 10.2147/JPR.S55201 -
Decoding Chronic Pain States from Distributed Intracranial Recordings
Spontaneous chronic pain states can be decoded from distributed intracranial LFPs across multi-day recordings in humans, with pain-predictive activity broadly distributed but enriched within the default mode network beta band and the salience network high-gamma band, and with th…
DOI: 10.64898/2026.06.16.732555 -
Long-Term Results of Deep Brain Stimulation of the Anterior Cingulate Cortex for Neuropathic Pain
This study evaluates the long-term efficacy of Deep Brain Stimulation (DBS) of the Anterior Cingulate Cortex in alleviating chronic neuropathic pain and improving quality of life in patients refractory to pharmacotherapy.
DOI: 10.1016/j.wneu.2017.06.173